Form 4: Hologic Merger Completes, CEO's Ownership Changes

Stephen P. MacMillan, Chairman, President and CEO of Hologic Inc., reports changes in beneficial ownership following the company's merger, with all common stock and options converted to cash and contingent value rights.

Summary

• This filing details changes in beneficial ownership for Stephen P. MacMillan, Chairman, President and CEO of Hologic Inc., following the completion of the merger between Hologic and Hopper Parent Inc. on April 7, 2026.
• As a result of the merger, each share of Hologic common stock was converted into $76.00 in cash and one contingent value right (CVR) potentially worth up to $3.00.
• All outstanding stock options held by Mr. MacMillan were cancelled and converted into cash payments and CVRs, depending on their exercise price relative to the merger consideration.
• Performance Stock Units (PSUs) were also converted into the right to receive the merger consideration, with performance goals deemed achieved at the greater of target or actual levels.
• Following the merger, Mr. MacMillan no longer beneficially owns any shares of Hologic common stock directly or indirectly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily reflecting the completion of a merger transaction that provides a clear cash payout to executives and shareholders, though the CVR component introduces some uncertainty.

Positives

• The merger with Hopper Parent Inc. has been successfully completed, providing shareholders with cash and contingent value rights.
• The transaction offers a significant cash payout of $76.00 per share, plus potential additional value from CVRs.
• Performance metrics for PSUs were recognized favorably, with goals deemed achieved at target or actual levels, maximizing potential payout.

Negatives

• All direct and indirect beneficial ownership of Hologic common stock by the reporting person has ceased due to the merger.
• Options with exercise prices at or above the sum of cash consideration and $3.00 were cancelled for no consideration.

Risks

• The value of the Contingent Value Rights (CVRs) is not guaranteed and depends on future events and conditions, with a maximum potential payout of $3.00 per share.
• The filing does not detail specific performance metrics or conditions for the CVRs, introducing uncertainty regarding their ultimate value.

Future Outlook

The future outlook for the reporting person is no longer tied to Hologic's stock performance, as all equity holdings have been converted into cash and CVRs. The value of the CVRs remains contingent on specific future events.

Management Comments

• The filing indicates that as a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
• Performance goals for PSUs were deemed achieved at the greater of the target level or actual level of performance measured through the latest practicable date prior to the Effective Time.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a significant corporate event, the completion of a merger, which is a common strategic move in the healthcare and technology sectors. Such transactions often lead to changes in executive compensation structures and beneficial ownership reporting as companies transition to private ownership or are acquired.

Comparison to Industry Standards

• The merger consideration of $76.00 per share in cash plus a CVR is a common structure for acquisition deals, aiming to bridge valuation gaps between buyers and sellers.
• The conversion of stock options and RSUs into cash and CVRs aligns with industry practices for executive compensation during M&A events.
• The structure of CVRs, offering potential future payouts based on specific milestones, is also a recognized mechanism in the industry to incentivize continued performance or to account for uncertain future value.

Stakeholder Impact

• Shareholders: Receive $76.00 per share in cash and one CVR per share, providing immediate liquidity and potential for future upside.
• Employees: Compensation tied to stock options and RSUs will be converted into cash and CVRs, impacting their equity-based compensation.
• Management: Stephen P. MacMillan's beneficial ownership in Hologic Inc. has been converted to cash and CVRs, changing his direct financial ties to the company's future stock performance.

Next Steps

• Shareholders will receive the cash consideration and CVRs as per the merger agreement.
• The reporting person will no longer be subject to Section 16 reporting requirements for Hologic Inc. common stock.

Key Dates

Keywords

Hologic Inc, HOLX, Form 4, Merger, Stephen P. MacMillan, Beneficial Ownership, Stock Options, Performance Stock Units, Contingent Value Rights, SEC Filing